• Publications
  • Influence
Selective JAK inhibitors in development for rheumatoid arthritis
  • P. Norman
  • Medicine
  • Expert opinion on investigational drugs
  • 11 July 2014
Introduction: The JAK kinases are a family of four tyrosine receptor kinases that play a pivotal role in cytokine receptor signalling pathways via their interaction with signal transducers andExpand
  • 101
  • 9
A second cysteinyl leukotriene receptor in human lung.
Leukotrienes (LT) are potent spasmogenic agents in human isolated bronchial and pulmonary venous muscle preparations. Treatment of human isolated pulmonary veins with the L-serine borate complex (45Expand
  • 159
  • 8
BAY u9773, a novel antagonist of cysteinyl-leukotrienes with activity against two receptor subtypes.
The effects of BAY u9773 (6(R)-(4'-carboxyphenylthio)-5(S)-hydroxy-7(E),9(E), 11(Z),14(Z)-eicosatetraenoic acid), a cysteinyl-leukotriene analogue, were investigated on a variety of smooth muscleExpand
  • 83
  • 6
BAY u3405, a potent and selective thromboxane A2 receptor antagonist on airway smooth muscle in vitro
1 BAY u3405 (3(R)‐[[(4‐fluorophenyl) sulphonyl]amino]‐1,2,3,4‐tetrahydro‐9H‐carbazole‐9‐propanoic acid) has been evaluated on airway smooth muscle, from a number of species including man, for itsExpand
  • 81
  • 4
Selective PI3Kδ inhibitors, a review of the patent literature
  • P. Norman
  • Biology, Medicine
  • Expert opinion on therapeutic patents
  • 22 October 2011
Introduction: Phosphatidylinositol 3-kinase (PI3K), a lipid kinase, is the first kinase involved in, and a key component of, the PI3K/Akt/mTOR signalling pathway, and is significantly upregulated inExpand
  • 52
  • 4
Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease
  • P. Norman
  • Medicine
  • Expert opinion on investigational drugs
  • 12 February 2015
Introduction: The p38 protein kinases, in particular p38α and p38β, regulate the production of multiple inflammatory mediators. Consequentially, considerable effort has been focused on trying toExpand
  • 44
  • 4
Selective JAK1 inhibitor and selective Tyk2 inhibitor patents
  • P. Norman
  • Medicine
  • Expert opinion on therapeutic patents
  • 21 September 2012
Introduction: The JAK family comprises of the four non-receptor tyrosine kinases JAK1, JAK2, JAK3 and Tyk2, which play key, but differing, roles in cytokine receptor signal transduction. AExpand
  • 33
  • 3
OSI-774 OSI Pharmaceuticals.
  • P. Norman
  • Medicine
  • Current opinion in investigational drugs
  • 1 February 2001
OSI-774 (formerly CP-358774), a quinazoline derivative, is an orally active epidermal growth factor receptor (EGFR) inhibitor which was originally under joint development by Pfizer and OSIExpand
  • 26
  • 2
Natural Products as a Source of New Drugs.
  • P. Norman
  • Engineering, Medicine
  • Drug news & perspectives
  • 1 September 2002
Drugs from Natural Products III, held July 14­16, 2002, in Dublin, Ireland, was organized by the Royal Society of Chemistry's Industrial Affairs Division and Biological and Medicinal ChemistryExpand
  • 60
  • 2
The thromboxane receptors of rat and guinea-pig lung.
The thromboxane (TXA2) receptors on rat and guinea-pig lung strips were compared using TXA2 agonists and TXA2 receptor antagonists. On rat lung strip several TXA2 mimetics were full agonists whilstExpand
  • 14
  • 2
...
1
2
3
4
5
...